QEL-001 clinical trials

Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients

This study looks into a new treatment called QEL-001 for people who have had a liver transplant. The aim is to see if QEL-001, made from the patient's own cells, can help prevent the body from rejecting the new liver, especially when usual anti-rejection medicines are reduced or stopped.